Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(3.08)
# 1,340
Out of 4,761 analysts
467
Total ratings
38.33%
Success rate
2.71%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Reiterates: Buy | $25 | $2.06 | +1,113.59% | 24 | Feb 18, 2025 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $30 → $3 | $1.56 | +92.31% | 16 | Feb 18, 2025 | |
| NMRA Neumora Therapeutics | Reiterates: Buy | $30 | $1.80 | +1,566.67% | 5 | Feb 14, 2025 | |
| EOLS Evolus | Reiterates: Buy | $27 | $13.99 | +93.00% | 25 | Feb 14, 2025 | |
| RZLT Rezolute | Reiterates: Buy | $14 | $4.53 | +209.05% | 16 | Feb 13, 2025 | |
| ALKS Alkermes | Reiterates: Neutral | $46 | $35.32 | +30.24% | 23 | Feb 13, 2025 | |
| APLS Apellis Pharmaceuticals | Reiterates: Buy | $57 | $27.52 | +107.12% | 25 | Feb 13, 2025 | |
| SAGE Sage Therapeutics | Reiterates: Neutral | $14 → $12 | $7.31 | +64.16% | 22 | Feb 12, 2025 | |
| ROIV Roivant Sciences | Reiterates: Buy | $18 | $10.68 | +68.54% | 17 | Feb 11, 2025 | |
| IMVT Immunovant | Reiterates: Buy | $51 | $21.27 | +139.77% | 21 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $38.75 | +29.03% | 26 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.07 | +554.21% | 23 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $54.53 | +116.39% | 14 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $670 → $717 | $644.48 | +11.25% | 33 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $37.46 | +116.23% | 23 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $13.02 | +45.93% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $16.27 | +108.97% | 15 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $59 | $36.91 | +59.85% | 13 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $3.17 | +278.55% | 16 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $39.73 | +33.40% | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $120 | $74.49 | +61.10% | 21 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.25 | +453.85% | 11 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $4.44 | +80.18% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.82 | +174.73% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.12 | +4,056.28% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $9.32 | +61.03% | 13 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.30 | +669.23% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $10 | $13.17 | -24.07% | 7 | Dec 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $201.39 | -9.63% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $5.19 | +261.27% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $22.50 | -20.00% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $16.74 | -52.21% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $25.16 | +106.68% | 2 | Jun 11, 2019 |
Cabaletta Bio
Feb 18, 2025
Reiterates: Buy
Price Target: $25
Current: $2.06
Upside: +1,113.59%
Outlook Therapeutics
Feb 18, 2025
Maintains: Buy
Price Target: $30 → $3
Current: $1.56
Upside: +92.31%
Neumora Therapeutics
Feb 14, 2025
Reiterates: Buy
Price Target: $30
Current: $1.80
Upside: +1,566.67%
Evolus
Feb 14, 2025
Reiterates: Buy
Price Target: $27
Current: $13.99
Upside: +93.00%
Rezolute
Feb 13, 2025
Reiterates: Buy
Price Target: $14
Current: $4.53
Upside: +209.05%
Alkermes
Feb 13, 2025
Reiterates: Neutral
Price Target: $46
Current: $35.32
Upside: +30.24%
Apellis Pharmaceuticals
Feb 13, 2025
Reiterates: Buy
Price Target: $57
Current: $27.52
Upside: +107.12%
Sage Therapeutics
Feb 12, 2025
Reiterates: Neutral
Price Target: $14 → $12
Current: $7.31
Upside: +64.16%
Roivant Sciences
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $10.68
Upside: +68.54%
Immunovant
Feb 10, 2025
Reiterates: Buy
Price Target: $51
Current: $21.27
Upside: +139.77%
Feb 7, 2025
Reiterates: Buy
Price Target: $50
Current: $38.75
Upside: +29.03%
Jan 23, 2025
Reiterates: Buy
Price Target: $7
Current: $1.07
Upside: +554.21%
Jan 21, 2025
Reiterates: Buy
Price Target: $118
Current: $54.53
Upside: +116.39%
Jan 14, 2025
Reiterates: Buy
Price Target: $670 → $717
Current: $644.48
Upside: +11.25%
Jan 13, 2025
Reiterates: Buy
Price Target: $81
Current: $37.46
Upside: +116.23%
Jan 13, 2025
Reiterates: Buy
Price Target: $19
Current: $13.02
Upside: +45.93%
Dec 17, 2024
Reiterates: Buy
Price Target: $34
Current: $16.27
Upside: +108.97%
Dec 17, 2024
Reiterates: Buy
Price Target: $59
Current: $36.91
Upside: +59.85%
Dec 17, 2024
Reiterates: Buy
Price Target: $12
Current: $3.17
Upside: +278.55%
Dec 12, 2024
Reiterates: Buy
Price Target: $53
Current: $39.73
Upside: +33.40%
Dec 12, 2024
Reiterates: Buy
Price Target: $120
Current: $74.49
Upside: +61.10%
Nov 14, 2024
Reiterates: Buy
Price Target: $18
Current: $3.25
Upside: +453.85%
Nov 7, 2024
Reiterates: Buy
Price Target: $8
Current: $4.44
Upside: +80.18%
Nov 6, 2024
Reiterates: Neutral
Price Target: $5
Current: $1.82
Upside: +174.73%
Oct 1, 2024
Reiterates: Buy
Price Target: $5
Current: $0.12
Upside: +4,056.28%
Sep 16, 2024
Reiterates: Buy
Price Target: $15
Current: $9.32
Upside: +61.03%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.30
Upside: +669.23%
Dec 9, 2021
Maintains: Neutral
Price Target: $23 → $10
Current: $13.17
Upside: -24.07%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $201.39
Upside: -9.63%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $5.19
Upside: +261.27%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $22.50
Upside: -20.00%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $16.74
Upside: -52.21%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $25.16
Upside: +106.68%